55417-50-0

Usage

InChI:InChI=1/C12H9Cl2NO2/c1-2-17-12(16)9(7-15)5-8-3-4-10(13)11(14)6-8/h3-6H,2H2,1H3/b9-5-

Upstream product

• 91183-45-8 ethyl 3-(3,4-dichlorophenyl)propiolate 
• 75-86-5 2-hydroxy-2-methylpropanenitrile 
• 6287-38-3 3,4-dichlorobenzaldehyde 
• 105-56-6 ethyl 2-cyanoacetate 
• 37630-53-8 (E)-2-cyano-3-(3,4-dichlorophenyl)acrylic acid 

Downstream Products

• 203317-12-8 2-Cyano-3-(3,4-dichloro-phenyl)-3-phenyl-propionic acid ethyl ester 
• 85662-98-2 3-(3',4'-dichlorophenyl)-indan-1-one 
• 80272-59-9 cis-3-(3,4-dichlorophenyl)-2,3-dihydro-1H-inden-1-ol 
• 86939-07-3 1-Chloro-3-(3,4-dichloro-phenyl)-indan 
• 80272-06-6 3-(3',4'-dichlorophenyl)-3-phenylpropanoic acid 
• 85663-53-2 (+)-trans-1-<3-(3,4-dichlorophenyl)indan-1-yl>-4-methylpiperazine 
• 85663-54-3 (+)-cis-1-<3-(3,4-dichlorophenyl)indan-1-yl>-4-methylpiperazine 
• 85663-55-4 2-{4-[(1R,3S)-3-(3,4-Dichloro-phenyl)-indan-1-yl]-piperazin-1-yl}-ethanol 
• 85663-56-5 2-{4-[(1S,3S)-3-(3,4-Dichloro-phenyl)-indan-1-yl]-piperazin-1-yl}-ethanol 
• 80273-19-4 3-{4-[(1R,3S)-3-(3,4-Dichloro-phenyl)-indan-1-yl]-piperazin-1-yl}-propan-1-ol 
• 85663-57-6 3-{4-[(1S,3S)-3-(3,4-Dichloro-phenyl)-indan-1-yl]-piperazin-1-yl}-propan-1-ol 
• 85663-58-7 1-[(1S,3R)-3-(3,4-Dichloro-phenyl)-indan-1-yl]-4-((E)-3-phenyl-allyl)-piperazine 
• 85663-59-8 1-[(1R,3R)-3-(3,4-Dichloro-phenyl)-indan-1-yl]-4-((E)-3-phenyl-allyl)-piperazine 
• 93553-81-2 3,4-dichlorophenylsuccinic acid 

Relevant academic research and scientific papers

Engineering cellulose into water soluble poly(protic ionic liquid) electrolytes in the DBU/CO2/DMSO solvent system as an organocatalyst for the Knoevenagel condensation reaction

The facile design and preparation of polyelectrolytes is a frontier topic in the fields of polymer science, energy storage devices and catalysis. Herein, linear water soluble cellulosic poly(protic ionic liquid) (CPIL) electrolytes were facilely and atom economically prepared after the dissolution of cellulose in the newly developed DBU/CO2/DMSO solvent system, followed by the simple addition of succinic anhydride under mild conditions. The DBU not only participated in the dissolution of cellulose as a solvent component, but also acted as an organocatalyst for the acylation reaction of cellulose with succinic anhydride, as well as a cation component in the targeted CPIL electrolytes. The reaction was optimized, and the effect of the reaction conditions on the chemical and physical properties of the CPILs was investigated. And then, as a proof of concept, the CPIL electrolyte aqueous solution was successfully used as the catalytic reaction media for the Knoevenagel condensation reaction. It was found that the reaction was homogeneous at the beginning, and the products could precipitate out from the media with the proceeding of the reaction, thus affording satisfactory filtration yields ranging from 56.7% to 93.8%. The solution properties of the CPIL aqueous solution were primarily investigated towards an in-depth understanding of the catalytic mechanism, by which a synergetic catalytic mechanism of the CPILs was proposed, and the reaction started with a nucleophilic addition reaction, and was then followed by a fast dehydration reaction. Finally, the direct reusability potential of the CPIL aqueous solution after the product filtration was also primarily investigated for the Knoevenagel condensation reaction.

A PEG bridged tertiary amine functionalized ionic liquid exhibiting thermoregulated reversible biphasic behavior with cyclohexane/isopropanol: Synthesis and application in Knoevenagel condensation

A novel poly(ethylene glycol) bridged tertiary amine functionalized ionic liquid PEG800-DPIL(Cl) was synthesized. It can form a temperature driven reversible biphasic system with cyclohexane/isopropanol mixed solvent. This biphasic system was applied in Knoevenagel condensation up to 99%. PEG 800-DPIL(Cl) could be simply recovered and recycled for several runs.

A highly efficient protocol for the regio- and stereo-selective synthesis of spiro pyrrolidine and pyrrolizidine derivatives by multicomponent reaction

A series of novel spiro[acenaphthylene-1,2′-pyrrolidine] (4), spiro[acenaphthylene-1,2′-pyrrolizidine] (7), and spiro[indoline-3, 2′-pyrrolidine] derivatives (9) containing cyano group were successfully synthesized via a three-component 1,3-dipolar cycloaddition reaction of acenaphthenequinone or isatin, sarcosine or proline, and Knoevenagel adducts in refluxing aqueous methanol. In this intermolecular three-component combinatorial process it is amazing that three stereogenic centers with one spiro carbon are controlled very well. The structure and relative stereo-chemistry of cycloadducts were carried out by single crystal X-ray diffraction, as well as by the help of 1H, 13C, and HMBC spectroscopy.

Synthesis of 5, 6-dichloroindan-1-acids and their tetrazolyl derivatives as analgesic and anti-inflammatory agents

Indan derivatives, namely, 5-(5′,6′-dichloroindan-1′-yl)- tetrazole (12a) and 5-(5′,6′-dichloroindan-1′-yl)- methyltetrazole (12b), were synthesized conveniently from 5,6-dichloroindan-1- carboxylic acid (9a) and 5,6- dichloroindan-1-acetic acid (9b), respectively, as potential analgesic and anti-inflammatory agents. The analgesic and anti-inflammatory properties of 9a, 9b, 12a and 12b were evaluated by the acetic acid induced writhing in Swiss albino mice and the carrageenan-induced rat paw edema models, respectively. Compounds 9a and 12a exhibited significant analgesic activity with the doses of 50 and 100 mg/kg body weight, comparable to that of the positive controls, phenylbutazone, indomethacin and aminopyrine. The anti-inflammatory potencies of 9a and 12a were also comparable to that of the positive control, phenylbutazone. Compounds 9b and 12b showed analgesic and anti-inflammatory activities, but were weaker than that of compounds 9a and 12a.

Design and an efficient synthesis of natural product-based cyclopenta[b]pyran derivatives with potential bioactivity

A series of 4-aryl-cyclopenta[b]pyran derivatives, designed based on natural product scaffold, were synthesized efficiently via multi-component reaction under solvent-free and catalyst-free conditions. This chemistry provides a new compound library with potential activity for biomedical screening.

A simple, efficient, and green protocol for Knoevenagel condensation in a cost-effective ionic liquid 2-hydroxyethlammonium formate without a catalyst

Knoevenagel condensation of aromatic aldehydes with active methylene compounds such as malononitrile, ethylcyanoacetate, and cyanoacetamide proceeded very smoothly in reusable and cheap ionic liquid 2-hydroxyethylammonium formate at room temperature in the absence of a catalyst. Compared to other reported ionic liquids, the ionic liquid 2-hydroxyethylammonium formate shows better potential in the applications on the industrial scale with its low cost and viscosity.

Green and efficient Knoevenagel condensation catalysed by a DBU based ionic liquid in water

An effi cient, clean and facile protocol for the Knoevenagel condensation of aromatic aldehydes with active methylene compounds catalysed by task specifi c ionic liquid 1,8-diazabicyclo[5.4.0]-undec-7-en-8-ium acetate in an aqueous medium has been developed. The reactions proceed at room temperature and high to excellent yields were afforded. The work-up procedure is very simple. The ionic liquid could be recycled for 10 runs without noticeably loss of its catalytic activity.

Phosphine-catalyzed reaction of cyanohydrins with activated alkynes

A new method for preparing α-cyanoacrylates and α-cyanoenones is described. The procedure uses a phosphine-catalyzed α-C addition of cyanide ion, generated in situ from cyanohydrins, to activated alkynes. An unexpected tandem reaction producing benzyliden

PYRIMIDINES AND THEIR USE AS CXCR2 RECEPTOR ANTAGONISTS

The present invention relates to compounds of formula (I) and the use of these compounds as pharmaceuticals, e.g. in preventing or treating a CXCR2 receptor mediated condition or disease.

INHIBITORS OF TNFα, PDE4 AND B-RAF, COMPOSITIONS THEREOF AND METHODS OF USE THEREWITH

Provided herein are compounds having TNFα and/or PDE4 and/or B-RAF inhibitory activity, and compositions thereof. In particular, provided herein are compounds of the formula (I) and pharmaceutically acceptable salts, solvates, hydrates, clathrates, stereoisomers, polymorphs and prodrugs thereof, wherein Ar, R1, R2, R3, R4, n and Z are as described herein. Further provided herein are methods for treating or preventing various diseases and disorders by administering to a patient one or more TNFα and/or PDE4 and/or B-RAF inhibitors. In particular, provided herein are methods for preventing or treating cancer, inflammatory disorders, cognition and memory disorders and autoimmune disorders, or one or more symptoms thereof by administering to a patient one or more TNFα and/or PDE4 and/or B-RAF inhibitors.